This inventor holds 1 USPTO granted patent. Top assignee: The University of Arizona. Active years: 2011.
Company Filing History:
Years Active: 2011
Title: Innovations of Wenqing Qi in Nucleophosmin Inhibition
Introduction
Wenqing Qi is an accomplished inventor based in Tucson, AZ (US). He has made significant contributions to the field of cancer research through his innovative work on nucleophosmin inhibitors. His research focuses on the mechanisms of apoptosis and cellular differentiation, which are crucial in understanding cancer progression.
Latest Patents
Wenqing Qi holds a patent titled "Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis." This patent discloses small molecule inhibitors that target the multimerization of nucleophosmin, thereby inhibiting its biological activity. The inhibitors are particularly useful for treating diseases associated with dysregulated nucleophosmin expression, such as cancer. One exemplary small molecule inhibitor mentioned in his patent is NSC348884, which has a specific chemical structure that enhances its efficacy.
Career Highlights
Wenqing Qi is affiliated with The University of Arizona, where he conducts his research. His work has garnered attention for its potential applications in cancer therapy. With a focus on innovative solutions, he continues to explore the therapeutic possibilities of nucleophosmin inhibitors.
Collaborations
Wenqing Qi has collaborated with notable colleagues, including Bogdan Z Olenyuk and Daruka Mahadevan. These collaborations have enriched his research and contributed to advancements in the understanding of nucleophosmin's role in cancer.
Conclusion
Wenqing Qi's innovative work on nucleophosmin inhibitors represents a significant advancement in cancer research. His contributions have the potential to lead to new therapeutic strategies for treating cancer and improving patient outcomes.